$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-031/497
출원번호 US-0627358 (2003-07-25)
등록번호 US7973043 (2011-06-22)
발명자 / 주소
  • Migaly, Peter
인용정보 피인용 횟수 : 52  인용 특허 : 18

초록

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics o

대표청구항

What is claimed is: 1. A method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physi

이 특허에 인용된 특허 (18)

  1. Yelle William E., 2-hydroxymethylolanzapine compositions and methods.
  2. Blum Kenneth (San Antonio TX) Noble E. P. (Los Angeles CA) Sheridan P. J. (San Antonio TX), Allelic association of the human dopamine(D2) receptor gene in compulsive disorders.
  3. Gerard Raphael Dawson GB, Combination of a GABA-A .alpha. 2/3 agonist and a selective serotonin reuptake inhibitor.
  4. Bymaster Franklin P. ; Perry Kenneth W. ; Tollefson Gary D., Combination therapy for treatment of psychoses.
  5. Tollefson, Gary Dennis, Combination therapy for treatment of refractory depression.
  6. William E. Yelle, Desmetylolanzapine compositions and methods.
  7. DeNinno Michael P. (Gales Ferry CT) Perner Richard J. (Gurnee IL), Dopamine agonists.
  8. Norden Michael J. (348 NW. 113th Pl. Seattle WA 98177), Method for treating borderline personality disorder with serotonin re-uptake blockers.
  9. Tollefson Gary D, Method for treating depression with olanzapine.
  10. Beasley Charles M ; Rasmussen Kurt ; Tollefson Gary D, Method for treating substance abuse.
  11. Sparhawk ; Jr. G. Roger, Method of diagnosing, tracking, and treating depression.
  12. Gina Guadagno ; Jodi M. Star, Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications.
  13. Eswara Amruta R. ; Muni Neal ; Schneider F. Howard ; Mione Peter J., Methods and articles of manufacture for nicotine cessation and monitoring nicotine use.
  14. William E. Yelle, Olanzapine-N-oxide compositions and methods.
  15. Yelle William E., Olanzapine-N-oxide compositions and methods.
  16. Hirsh, Mark; Midha, Kamal K.; Junginger, Hans E., Pharmaceutical composition containing two active ingredients for smoking cessation.
  17. Perry Kenneth Wayne, Potentiation of pharmaceuticals.
  18. Wiech Norbert L. (Cincinnati OH) Ursillo Richard C. (Cincinnati OH), TCA Composition and method for rapid onset antidepressant therapy.

이 특허를 인용한 특허 (52)

  1. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  2. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  3. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  4. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  5. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  6. Tabuteau, Herriot, Bupropion as a modulator of drug activity.
  7. Tabuteau, Herriot, Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan.
  8. Tabuteau, Herriot, Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan.
  9. Tabuteau, Herriot, Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan.
  10. Tabuteau, Herriot, Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan.
  11. Tabuteau, Herriot, Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan.
  12. Tabuteau, Herriot, Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects.
  13. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  14. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  15. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  16. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  17. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  18. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  19. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  20. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  21. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  22. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  23. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  24. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  25. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  26. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects.
  27. Tabuteau, Herriot, Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects.
  28. Eichele, Gregor; Oster, Henrik; Kiessling, Silke, Compositions and methods for modulating circadian synchronization.
  29. Eichele, Gregor; Oster, Henrik; Kiessling, Silke, Compositions and methods for modulating circadian synchronization.
  30. Tabuteau, Herriot, Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects.
  31. Tabuteau, Herriot, Compositions and methods of using threohydroxybupropion for therapeutic purposes.
  32. Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Distillation of status data relating to regimen compliance responsive to the presence and absence of wireless signals relating to one or more threshold frequencies.
  33. Castro, Ramiro; Ceci, Angelo, Flibanserin for the treatment of urinary incontinence and related diseases.
  34. Castro, Ramiro; Ceci, Angelo, Flibanserin for the treatment of urinary incontinence and related diseases.
  35. Tabuteau, Herriot, Hydroxybupropion and related compounds as modulators of drug plasma levels.
  36. Drevets, Wayne C.; Li, Qingqin S., Method for the treatment of depression.
  37. Charney, Dennis S.; Mathew, Sanjay J.; Manji, Husseini K.; Zarate, Carlos A.; Krystal, John H., Methods for treating suicidal ideation.
  38. Tabuteau, Herriot, Methods of modulating drug plasma levels using erythrohydroxybupropion.
  39. Moskal, Joseph, Methods of treating depression and other related diseases.
  40. Moskal, Joseph, Methods of treating depression and other related diseases.
  41. Moskal, Joseph, Methods of treating depression and other related diseases.
  42. Moskal, Joseph R., Methods of treating depression and other related diseases.
  43. Moskal, Joseph R., Methods of treating depression and other related diseases.
  44. Mazurek, Jaroslaw; Pop, Mihaela, Salts.
  45. Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
  46. Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
  47. Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
  48. Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data responsive to whether or not a wireless signal has been received and relating to regimen compliance.
  49. Borsini, Franco; Evans, Kenneth Robert, Treating sexual desire disorders with flibanserin.
  50. Borsini, Franco; Evans, Kenneth Robert, Treating sexual desire disorders with flibanserin.
  51. Hanes, Vladimir; Verbeek, Anna Elizabeth, Treatment of vasomotor symptoms.
  52. Ceci, Angelo; Schindler, Marcus, Use of flibanserin in the treatment of obesity.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트